Table 1.
Clinicopathologic characteristics according to Hans classification in diffuse large B cell lymphoma patients
| Clinicopathologic characteristics | Total | GCB | Non-GCB | p-value |
|---|---|---|---|---|
| Age | ||||
| ≤ 60 | 53 (50%) | 17 (63%) | 31 (43%) | 0.078# |
| > 60 | 54 (50%) | 10 (37%) | 41 (57%) | |
| Sex | ||||
| Male | 61 (57%) | 7 (26%) | 34 (47%) | 0.055# |
| Female | 46 (43%) | 20 (74%) | 38 (53%) | |
| Primary site | ||||
| Nodal | 54 (50%) | 23 (85%) | 51 (71%) | 0.196† |
| Extranodal | 53 (49%) | 4 (15%) | 21 (29%) | |
| B symptoms | ||||
| Absent | 85 (79%) | 25 (93%) | 55 (76%) | 0.088† |
| Present | 22 (21%) | 2 (7%) | 17 (24%) | |
| ECOG PS | ||||
| < 2 | 97 (91%) | 26 (96%) | 64 (89%) | 0.437† |
| ≥ 2 | 10 (9%) | 1 (4%) | 8 (11%) | |
| Serum lactate dehydrogenase | ||||
| Normal | 54 (50%) | 18 (69%) | 32 (46%) | 0.040# |
| Elevated | 50 (47%) | 8 (31%) | 38 (54%) | |
| Unknown | 3 (3%) | |||
| No. of extranodal sites | ||||
| < 2 | 81 (76%) | 17 (63%) | 33 (46%) | 0.129# |
| ≥ 2 | 26 (24%) | 10 (37%) | 39 (54%) | |
| Ann Arbor stage | ||||
| I–II | 56 (52%) | 17 (63%) | 35 (49%) | 0.203† |
| III–IV | 51 (48%) | 10 (37%) | 37 (51%) | |
| International prognostic index | ||||
| 0–2 | 71 (66%) | 22 (81%) | 44 (61%) | 0.056# |
| 3–5 | 36 (34%) | 5 (19%) | 28 (39%) | |
| Bone marrow involvement | ||||
| Absent | 84 (79%) | 25 (96%) | 55 (85%) | 0.168† |
| Present | 14 (13%) | 1 (4%) | 10 (15%) | |
| Unknown | 9 (8%) | |||
| Bulky mass (cm) | ||||
| < 10 | 98 (92%) | 25 (93%) | 66 (92%) | > 0.999† |
| ≥10 | 9 (8%) | 2 (7%) | 6 (8%) | |
| Hans classification | ||||
| GCB | 27 (25%) | 27 (100%) | 0 (0%) | NA |
| Non-GCB | 72 (67%) | 0 (0%) | 72 (100%) | |
| Unclassifiable | 8 (8%) | |||
| BCL2 expression | ||||
| Negative | 42 (39%) | 13 (50%) | 24 (33%) | 0.133# |
| Positive | 65 (61%) | 13 (50%) | 48 (67%) | |
| BCL6 expression | ||||
| Negative | 60 (56%) | 8 (30%) | 44 (61%) | 0.005# |
| Positive | 47 (44%) | 19 (70%) | 28 (39%) | |
| CD10 expression | ||||
| Negative | 92 (86%) | 12 (44%) | 72 (100%) | < 0.001† |
| Positive | 15 (14%) | 15 (56%) | 0 (0%) | |
| MUM1 expression | ||||
| Negative | 41 (38%) | 25 (93%) | 8 (11%) | < 0.001† |
| Positive | 66 (62%) | 2 (7%) | 64 (89%) | |
| Treatment regimen | ||||
| R-CHOP | 93 (87%) | 23 (85%) | 64 (89%) | 0.731† |
| Others | 14 (13%) | 4 (15%) | 8 (11%) | |
| Total N (%) | 107 (100%) | |||
NA: not applicable; ECOG PS: the Eastern Cooperative Group Performance Status; GCB: germinal center B-cell like; R-CHOP: rituximab with cyclophosphamide–doxorubicin–vincristine–prednisone, GI: gastrointestinal
p values were calculated by using Fisher’s exact test (2-sided)† or Pearson’s Chi square test (2-sided)#